Eric D. Shaff Receives Stock Award at Seres Therapeutics Inc (MCRB) — SEC Form 4, Feb 07, 2023

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Eric D. Shaff

CEO

TXN 2023-02-03 · FILED 2023-02-07

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Seres Therapeutics Inc

MCRB CIK 0001609809

Reporting Owner

Name	Relationship
Eric D. Shaff CIK 0001643734	Director CEO

Eric D. Shaff at Seres Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $9,095

More from this insider at Seres Therapeutics Inc

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Restricted Stock UnitsF1 F2 F2		2023-02-03	A - Award/Grant	125,000 A	$0.00		125,000 Common Stock	Direct
Stock Option (Right to Buy)F3	$5.50	2023-02-03	A - Award/Grant	250,000 A	$0.00	2033-02-02	250,000 Common Stock	Direct

Footnotes (3)

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Show more
F2: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Show more
F3: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Show more

Institutional Holders

Largest by reported value

Other insiders at Seres Therapeutics Inc

GET /v1/forms/4/0000899243-23-004206 API docs